21.00
-0.57%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Shenzhen Chipscreen Biosciences Co
Its shares trade on Shanghai under the ticker 688321.SS. It has been listed since 12 August 2019. In the fiscal year to 31 December 2025, it reported revenue of CN¥909.5m and net income of CN¥51.1m. At that date it held total assets of CN¥3.65bn and shareholders' equity of CN¥1.66bn.
Shenzhen Chipscreen Biosciences Co., Ltd. engages in the research, development, and sale of small molecule drugs. The company is headquartered in Shenzhen, Guangdong. The company went IPO on 2019-08-12. The firm focuses on the research and development of original innovative drugs in five therapeutic areas, including malignant tumors, metabolic diseases, autoimmune diseases, central nervous system diseases and anti-virus. The firm's main products include Chidamide, Siglitazone, Cioroni and CS12192. The firm mainly conducts its businesses in the domestic market.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 12 Aug 2019
- Employees
- 1,045
- Website
- chipscreen.com ↗
Leadership
Pay as last reported
- Mr. Xianping LuChairman of the Board, General Manager, since 2018¥3.4m
- Mr. Jianxun LiFinance Director, Deputy General Manager, Director, since 2018¥1.3m
- Mr. Desi PanChief Scientific Officer, Deputy General Manager¥1.2m
- Ms. Ou HaiDeputy General Manager, Secretary of the Board, Director, since 2018¥1.0m
- Mr. Zhibin LiDeputy General Manager¥1.4m
- Mr. Liangji SheDeputy General Manager¥1.5m
- Mr. Libin ZhangDeputy General Manager¥1.4m
- Mr. Weihua LiDirector
- Mr. Hanpeng YangDirector¥96,000
- Ms. Xiangyan LiIndependent Director¥150,000
- Mr. Ruilin SongIndependent Director¥150,000
- Mr. Xun ZhuIndependent Director¥150,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 66
- Environment
- 85
- Social
- 57
- Governance
- 56
- Direct emissions (scope 1)
- 292.31 t
- Energy emissions (scope 2)
- 4,315.77 t
- Women in the workforce
- 48.96226%
- Carbon reduction policy
- Yes
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Shenzhen Chipscreen Biosciences employs 1045 employees in Health Care sector.
- Chidamide and Siglitazone are key products in malignant tumor treatment.
- Chipscreen focuses on five therapeutic areas including autoimmune diseases.
Weaknesses
- Shenzhen Chipscreen operates solely in the domestic market with no international presence.
- The company's main products are limited to four drugs including Cioroni.
- Chipscreen has no presence in the Financials or Real Estate sectors.
Opportunities
- Expanding into the Information Technology sector for drug development.
- Growing demand for anti-virus drugs in the global market.
- Increasing focus on central nervous system diseases in Health Care.
Threats
- Competition from other Health Care companies in China.
- Rising costs in the Pharmaceuticals industry.
- Regulatory changes affecting drug approvals in CN.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.